Naproxen 250mg relieves menstruation and pain relief and analgesics (the same ingredients worship the ear pain, the picture is for reference only, random packaging and delivery)
Naproxen 250mg relieves menstruation and pain relief and analgesics (the same ingredients worship the ear pain, the picture is for reference only, random packaging and delivery)
销售 33%
Naproxen 250mg relieves menstruation and pain relief and analgesics (the same ingredients worship the ear pain, the picture is for reference only, random packaging and delivery)
Naproxen 250mg relieves menstruation and pain relief and analgesics (the same ingredients worship the ear pain, the picture is for reference only, random packaging and delivery)
库存仅剩-3 售罄

萘普生(Naproxen) 250mg 腰痛背痛缓解月经例假痛止疼镇痛 (拜耳痛经小蓝片同样成分,图片仅供参考,随机包装发货)

£19.99 £29.99 £19.99 售罄
- +
This is a prescription product provided through pharmacist assessment under an approved treatment plan.
Continue to Assessment
存货单位 WY0033095S
顾客还购买了
对于直邮到中国的订单,请访问我们的国际网站
Frequently Asked Questions
使用萘普生期间,我能做些什么来预防副作用?
chevron-down
为降低胃部刺激等副作用的风险,请务必随餐服用萘普生,并避免饮酒或同时使用其他非甾体抗炎药(NSAIDs)。保持充足水分摄入并使用最低有效剂量也有助于降低风险。点击「开始咨询」,制定安全且个人化的治疗方案。
订购萘普生后的过程为何?
chevron-down
一旦开始咨询,您将填写一份简短的健康问卷,选择并支付治疗费用,我们的团队将审核订单以确保安全。如果布洛芬不适合您,药剂师将建议替代方案。一旦批准,您的药物将被寄出——无需进一步操作。
我该如何服用萘普生来缓解疼痛?
chevron-down
萘普生通常每日服用1至2次,建议随餐或与牛奶同服以减轻胃部不适。剂量需根据病情及症状严重程度调整。立即咨询以选择并支付治疗方案——我们的团队将确保方案的适宜性,并在审批通过后直接寄送至您家中。
谁可服用萘普生,以及服用萘普生的风险有哪些?
chevron-down
萘普生对健康成年人通常是安全的,但可能不适合患有胃溃疡、心脏问题或肾脏疾病的人群。它还可能与其他药物发生相互作用。点击「开始咨询」,以便我们的团队评估萘普生是否适合您。如果不适合,药剂师将在发货前为您推荐更安全的替代方案。
萘普生是什么,它的用途是什么?
chevron-down
萘普生是一种非甾体抗炎药(NSAID),用于缓解关节炎、肌肉酸痛、痛经和头痛等引起的疼痛、肿胀和僵硬。它通过减少炎症和阻断疼痛信号来发挥作用。 开始使用时,点击「开始咨询」”,选择并支付您的药物,我们的团队将审核您的信息以确保安全后再发货。
Reviewed by
Chenyang Ma
Chenyang Ma
MPharm
Superintendent Pharmacist
Chenyang Ma is a GPhC-registered Superintendent Pharmacist at Ways Pharmacy in London. With a Master of Pharmacy (MPharm) from the University of Nottingham (2013), he combines strong commercial acumen and clinical expertise to drive patient-centric pharmacy services.
Reviewed Date
04 June 2025
Next Review
04 June 2026
Published On
04 June 2025
Last Updated
04 June 2025